Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors during the central nervous system, conolidine modulates alternate molecular targets. A Science Improvements review observed that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By i... https://germainer172pqu4.wikisona.com/user